Another recent study demonstrated the O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status determined by PCR in tumor tissue from primary melanomas as a predictive marker of response to temozolomide, an oral derivative of DTIC [21]. Here, MGMT is linked to melanoma.